WHAT IS CLAIMED IS:

1. A method for treating bedwetting in a subject, comprising:

administering to a subject in need thereof a pharmaceutical composition comprising:

an active ingredient comprising one or more analgesic agents in an amount of 1-1000 mg per agent, wherein said one or more analgesic agents are selected from the group consisting of aspirin, ibuprofen, naproxen, naproxen sodium, indomethacin, nabumetone, and acetaminophen.

2. The method of Claim 1, wherein said pharmaceutical composition is formulated for extended-release such that said active ingredient is released continuously over a period of 2-12 hours.

3. The method of Claim 2, wherein said pharmaceutical composition is further coated with an enteric coating.

4. The method of Claim 1, wherein said pharmaceutical composition is formulated for extended release, characterized by a two-phase release profile in which 20-60% of said active ingredient is released within two hours of administration and remainder of said active ingredient is released continuously over a period of 2-12 hours.

5. The method of Claim 4, wherein said pharmaceutical composition is coated with an enteric coating.

6. The method of Claim 1, wherein said pharmaceutical composition is formulated for delayed-release.

7. The method of Claim 1, wherein said one or more analgesic agents consist of acetaminophen.

8. The method of Claim 7, wherein said one or more analgesic agents consist of acetaminophen in an amount of 3-300 mg.

9. The method of Claim 1, wherein said one or more analgesic agents consist of acetaminophen and one other analgesic agent selected from the group consisting of aspirin, ibuprofen, naproxen, naproxen sodium, indomethacin, and nabumetone.

10. The method of Claim 1, wherein said active ingredient further comprises an antimuscarinic agent.

11. The method of Claim 1, wherein said active ingredient further comprises an antidiuretic.

12. The method of Claim 11, wherein said antidiuretic is desmopressin.

13. The method of Claim 1, wherein said active ingredient further comprises a spasmolytic.

14. The method of Claim 1, wherein said active ingredient further comprises an inhibitor of phosphodiesterase type 5 (PDE 5 inhibitor).

15. The method of Claim 14, wherein said PDE 5 inhibitor is tadalafil.

16. The method of Claim 1, wherein said active ingredient further comprises two additional agents selected from the group consisting of an antimuscarinic agent, an antidiuretic, a spasmolytic and a PDE 5 inhibitor.

17. The method of Claim 1, wherein said pharmaceutical composition is formulated for immediate-release.

18. A method for treating bedwetting in a subject, comprising:

administering to a subject in need thereof a pharmaceutical composition comprising:

a first active ingredient comprising one or more agents selected from the group consisting analgesic agents, antimuscarinic agents, antidiuretics, spasmolytics and PDE 5 inhibitors; and

a second active ingredient comprising one or more agents selected from the group consisting of analgesic agents, antimuscarinic agents, antidiuretics, spasmolytics and PDE 5 inhibitors,

wherein said first active ingredient is formulated for immediate release and wherein said second active ingredient is formulated for extended release.

19. The method of Claim 18, wherein said pharmaceutical composition is further coated with an enteric coating.

20. The method of Claim 18, wherein said first active ingredient comprises an analgesic.

21. The method of Claim 20, wherein said first active ingredient further comprises an antimuscarinic agent.

22. The method of Claim 20, wherein said active ingredient further comprises an antidiuretic.

23. The method of Claim 22, wherein said antidiuretic is desmopressin.

24. The method of Claim 18, wherein said first active ingredient further comprises a spasmolytic.

25. The method of Claim 18, wherein said first active ingredient further comprises a PDE 5 inhibitor.

26. The method of Claim 25, wherein said PDE 5 inhibitor is tadalafil.

27. A pharmaceutical composition, comprising:

one or more analgesic agents;

desmopressin; and

a pharmaceutically acceptable carrier.

28. The pharmaceutical composition of Claim 27, wherein said one or more analgesic agents are formulated for extended release and wherein said desmopressin is formulated for immediate release.

29. The pharmaceutical composition of Claim 27, wherein said one or more analgesic agents and said desmopressin are formulated for extended release over a period of 2-12 hours.

30. The pharmaceutical composition of Claim 27, wherein said desmopressin and 20-60% of each of said one or more analgesic agents are formulated for immediate release, and wherein remainder of each of said one or more analgesic agents is formulated for extended release.

31. The pharmaceutical composition of Claim 27, wherein said pharmaceutical composition is coated with an enteric coating.

AMENDED CLAIMS
received by the International Bureau on 31 December 2013 (31.12.2013)

1. Use of a pharmaceutical composition for treating bedwetting in a subject, said pharmaceutical composition comprising:

an active ingredient-comprising one or more analgesic agents in an amount of 1-1000 mg per agent, wherein said one or more analgesic agents are selected from the group consisting of aspirin, ibuprofen, naproxen, naproxen sodium, indomethacin, nabumetone, and acetaminophen.

2. The use of Claim 1, wherein said pharmaceutical composition is formulated for extended-release such that said active ingredient is released continuously over a period of 2-12 hours.

3. The use of Claim 2, wherein said pharmaceutical composition is further coated with an enteric coating.

4. The use of Claim 1, wherein said pharmaceutical composition is formulated for extended release, characterized by a two-phase release profile in which 20-60% of said active ingredient is released within two hours of administration and remainder of said active ingredient is released continuously over a period of 2-12 hours.

5. The use of Claim 4, wherein said pharmaceutical composition is coated with an enteric coating.

6. The use of Claim 1, wherein said pharmaceutical composition is formulated for delayed-release.

7. The use of Claim 1, wherein said one or more analgesic agents consist of acetaminophen.

8. The use of Claim 7, wherein said one or more analgesic agents consist of acetaminophen is in an amount of 3-300 mg.

9. The use of Claim 1, wherein said one or more analgesic agents consist of acetaminophen and one other analgesic agent selected from the group consisting of aspirin, ibuprofen, naproxen, naproxen sodium, indomethacin, and nabumetone.

10. The use of Claim 1, wherein said active ingredient further comprises an antimuscarinic agent.

11. The use of Claim 1, wherein said active ingredient further comprises an antidiuretic.

12. The use of Claim 11, wherein said antidiuretic is desmopressin.

13. The use of Claim 1, wherein said active ingredient further comprises a spasmolytic.

14. The use of Claim 1, wherein said active ingredient further comprises an inhibitor of phosphodiesterase type 5 (PDE 5 inhibitor).

15. The use of Claim 14, wherein said PDE 5 inhibitor is tadalafil.

16. The use of Claim 1, wherein said active ingredient further comprises two additional agents selected from the group consisting of an antimuscarinic agent, an antidiuretic, a spasmolytic and a PDE 5 inhibitor.

17. The use of Claim 1, wherein said pharmaceutical composition is formulated for immediate-release.

18. Use of a pharmaceutical composition for treating bedwetting in a subject,

said pharmaceutical composition comprising:

a first active ingredient comprising one or more agents selected from the group consisting analgesic agents, antimuscarinic agents, antidiuretics, spasmolytics and PDE 5 inhibitors; and

a second active ingredient comprising one or more agents selected from the group consisting of analgesic agents, antimuscarinic agents, antidiuretics, spasmolytics and PDE 5 inhibitors,

wherein said first active ingredient is formulated for immediate release and wherein said second active ingredient is formulated for extended release.

19. The use of Claim 18, wherein said pharmaceutical composition is further coated with an enteric coating.

20. The use of Claim 18, wherein said first active ingredient comprises an analgesic agent.

21. The use of Claim 20, wherein said first active ingredient further comprises an antimuscarinic agent.

22. The use of Claim 20, wherein said first active ingredient further comprises an antidiuretic.

23. The use of Claim 22, wherein said antidiuretic is desmopressin.

24. The use of Claim 18, wherein said first active ingredient further comprises a spasmolytic.

25. The use of Claim 18, wherein said first active ingredient further comprises a PDE 5 inhibitor.

26. The use of Claim 25, wherein said PDE 5 inhibitor is tadalafil.

27. A pharmaceutical composition for treating bedwetting, comprising:

one or more analgesic agents;

desmopressin; and

a pharmaceutically acceptable carrier,

wherein said pharmaceutical composition is formulated in a manner selected from the group consisting of: a) said one or more analgesic agents are formulated for extended release and wherein said desmopressin is formulated for immediate release, b) said one or more analgesic agents and said desmopressin are formulated for extended release over a period of 2-12 hours, and c) said desmopressin and 20-60% of each of said one or more analgesic agents are formulated for immediate release, and wherein remainder of each of said one or more analgesic agents is formulated for extended release.

28. The pharmaceutical composition of Claim 27, wherein said one or more analgesic agents are formulated for extended release and wherein said desmopressin is formulated for immediate release.

29. The pharmaceutical composition of Claim 27, wherein said one or more analgesic agents and said desmopressin are formulated for extended release over a period of 2-12 hours.

30. The pharmaceutical composition of Claim 27, wherein said desmopressin and 20-60% of each of said one or more analgesic agents are formulated for immediate release, and wherein remainder of each of said one or more analgesic agents is formulated for extended release.

31. The pharmaceutical composition of Claim 27, wherein said pharmaceutical composition is further coated with an enteric coating.

WHAT IS CLAIMED IS:

1. The use of a pharmaceutical composition comprising an active ingredient comprising one or more analgesic agents selected from the group consisting of aspirin, ibuprofen, naproxen, naproxen sodium, indomethacin, nabumetone and acetaminophen, in the manufacture of a medicament for the treatment of bedwetting.

2. The use of the pharmaceutical composition of Claim 1, wherein said pharmaceutical composition is formulated for immediate release.

3. The use of the pharmaceutical composition of Claim 1, wherein said pharmaceutical composition is formulated for extended-release.

4. The use of the pharmaceutical composition of Claim 2 or 3, wherein said pharmaceutical composition is further coated with an enteric coating.

5. The use of the pharmaceutical composition of Claim 1, wherein said pharmaceutical composition is formulated for delayed-release.

6. The use of the pharmaceutical composition of any one of Claims 1-5, wherein said pharmaceutical composition comprises one or more analgesic agents in an amount of 10-1000 mg per analgesic agent.

7. The use of the pharmaceutical composition of any one of Claims 1-6, wherein said one or more analgesic agents comprises acetaminophen.

8. The use of the pharmaceutical composition of Claim 7, wherein said pharmaceutical composition comprises acetaminophen in an amount of 10-300 mg.

9. The use of the pharmaceutical composition of Claim 7, wherein said pharmaceutical composition comprises acetaminophen in an amount of 300-1000 mg.

10. The use of the pharmaceutical composition of any one of Claims 1-9, wherein said one or more analgesic agents consist of acetaminophen and one other analgesic agent selected from the group consisting of aspirin, ibuprofen, naproxen, naproxen sodium, indomethacin, and nabumetone.

11. The use of the pharmaceutical composition of any one of Claims 1-10, wherein said active ingredient further comprises an antimuscarinic agent.

12. The use of the pharmaceutical composition of any one of Claims 1-11, wherein said active ingredient further comprises an antidiuretic.

13. The use of the pharmaceutical composition of any one of Claims 1-12, wherein said active ingredient further comprises a spasmolytic.

14. The use of the pharmaceutical composition of any one of Claims 1-13, wherein said active ingredient further comprises an inhibitor of phosphodiesterase type 5 (PDE 5 inhibitor).

15. The use of a pharmaceutical composition comprising an active ingredient comprising one or more analgesic agents in an amount of 1-1000 mg per agent in the manufacture of a medicament for treatment of bedwetting, wherein said one or more analgesic agents are selected from the group consisting of aspirin, ibuprofen, naproxen, naproxen sodium, indomethacin, nabumetone, and acetaminophen and wherein said pharmaceutical composition is formulated for immediate release, extended release, delayed release or combinations thereof.

16. The use of the pharmaceutical composition of Claim 15, wherein said one or more analgesic agents comprises acetaminophen.

17. The use of the pharmaceutical composition of Claim 16, wherein said one or more analgesic agents further comprises an analgesic agent selected from the group consisting of aspirin, ibuprofen, naproxen, naproxen sodium, indomethacin and nabumetone.

18. The use of the pharmaceutical composition of Claim 15-17, wherein said active ingredient further comprises an agent selected from the group consisting of antimuscarinic agents, antidiuretics, spasmolytics and PDE 5 inhibitors.

19. Pharmaceutical composition comprising:
one or more analgesic agents;
desmopressin; and
a pharmaceutically acceptable carrier,
wherein said pharmaceutical composition is formulated for immediate release, extended release, delayed release or combinations thereof, for use in the treatment of bedwetting.

20. The pharmaceutical composition of Claim 19, wherein said one or more analgesic agents comprises acetaminophen.

21. The use of the pharmaceutical composition of Claim 1, wherein said pharmaceutical composition is in a liquid or solid formulation.

22. The pharmaceutical composition of Claim 19, wherein said pharmaceutical composition is in a liquid or solid formulation.